AnHorn Medicines Begins AH-001 Phase I Clinical Trial with First Subject Dosed in US

TAIPEI, March 26, 2025 – AnHorn Medicines, renowned for its innovative use of artificial intelligence in drug discovery, has announced a significant milestone with AH-001, a revolutionary treatment for androgenetic alopecia (AGA). This promising first-in-class protein degrader has commenced Phase I clinical trials in the United States, with the inaugural participant receiving their first dose this week.

AH-001 distinguishes itself from conventional AGA treatments by utilizing a unique mechanism as a selective protein degrader. Traditional therapies often rely on enzyme inhibition or hair follicle stimulation, but AH-001 offers a novel approach by strategically targeting and removing specific proteins responsible for hair loss. This method could potentially provide a more effective and enduring solution for individuals affected by AGA globally.

The demand for advanced AGA treatments is on an upward trajectory, with forecasts indicating that the global market could surpass $10 billion by 2030. Existing treatments such as finasteride and minoxidil, while widely used, present limitations in terms of efficacy and side effects, highlighting a critical need for improved therapies. AH-001’s innovative strategy promises to revolutionize AGA treatment, offering substantial therapeutic benefits and potentially transforming patient care.

AnHorn Medicines attributes its achievements with AH-001 to its proprietary AI-powered drug discovery platform. By harnessing the power of artificial intelligence, the company has significantly expedited the identification of effective protein degraders, thereby streamlining the initial phases of drug development. This AI-driven methodology not only enhances the efficiency of drug discovery but also provides profound insights into complex biological pathways, reinforcing AnHorn's stature as a leader in next-generation therapeutic innovation.

The initiation of the Phase I clinical trial marks a pivotal moment for AnHorn, demonstrating its unwavering commitment to advancing AH-001 through rigorous clinical evaluation. The company is dedicated to bringing this transformative therapy to patients and will continue to share progress updates as the trial advances.

AnHorn Medicines operates as a clinical-stage biotechnology firm, focused on revolutionizing drug discovery through its AI-driven innovation. By merging artificial intelligence with state-of-the-art molecular research, AnHorn is at the forefront of developing groundbreaking treatments for conditions with significant unmet medical needs. AH-001 represents the company’s premier program emerging from its AI-driven platform, embodying AnHorn's mission to create transformative therapies that enhance patient outcomes.